Editas Medicine Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Editas Medicine wird ein jährliches Gewinn- und Umsatzwachstum von 2.5% bzw. 37.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -184.7% betragen.
Wichtige Informationen
1.5%
Wachstumsrate der Gewinne
12.4%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 28.4% |
Wachstumsrate der Einnahmen | 35.7% |
Zukünftige Eigenkapitalrendite | -184.7% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 19 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12Recent updates
Editas Medicine: A Risk/Reward Worth Considering
Sep 25Benign Growth For Editas Medicine, Inc. (NASDAQ:EDIT) Underpins Stock's 32% Plummet
Aug 23Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 45 | -276 | -311 | -257 | 13 |
12/31/2025 | 20 | -273 | -266 | -238 | 17 |
12/31/2024 | 26 | -245 | -185 | -177 | 18 |
6/30/2024 | 67 | -193 | -172 | -165 | N/A |
3/31/2024 | 69 | -166 | -151 | -146 | N/A |
12/31/2023 | 78 | -153 | -137 | -132 | N/A |
9/30/2023 | 25 | -195 | -156 | -152 | N/A |
6/30/2023 | 19 | -206 | -169 | -165 | N/A |
3/31/2023 | 23 | -219 | -168 | -164 | N/A |
12/31/2022 | 20 | -220 | -181 | -177 | N/A |
9/30/2022 | 26 | -201 | -176 | -170 | N/A |
6/30/2022 | 32 | -184 | -171 | -162 | N/A |
3/31/2022 | 26 | -186 | -174 | -164 | N/A |
12/31/2021 | 26 | -193 | -172 | -164 | N/A |
9/30/2021 | 24 | -214 | -176 | -169 | N/A |
6/30/2021 | 81 | -167 | -189 | -183 | N/A |
3/31/2021 | 92 | -135 | -180 | -175 | N/A |
12/31/2020 | 91 | -116 | -187 | -180 | N/A |
9/30/2020 | 92 | -91 | -106 | -99 | N/A |
6/30/2020 | 33 | -132 | -79 | -71 | N/A |
3/31/2020 | 24 | -142 | -73 | -66 | N/A |
12/31/2019 | 21 | -134 | -47 | -41 | N/A |
9/30/2019 | 14 | -121 | -86 | -80 | N/A |
6/30/2019 | 25 | -103 | -66 | -61 | N/A |
3/31/2019 | 30 | -108 | -57 | -52 | N/A |
12/31/2018 | 32 | -110 | -50 | -46 | N/A |
9/30/2018 | 29 | -121 | -76 | -72 | N/A |
6/30/2018 | 21 | -132 | -96 | -92 | N/A |
3/31/2018 | 17 | -120 | N/A | -102 | N/A |
12/31/2017 | 14 | -120 | N/A | -9 | N/A |
9/30/2017 | 11 | -124 | N/A | 2 | N/A |
6/30/2017 | 6 | -118 | N/A | 13 | N/A |
3/31/2017 | 6 | -111 | N/A | 29 | N/A |
12/31/2016 | 6 | -97 | N/A | -50 | N/A |
9/30/2016 | 6 | -71 | N/A | -45 | N/A |
6/30/2016 | 6 | -57 | N/A | -39 | N/A |
3/31/2016 | 2 | -86 | N/A | -9 | N/A |
12/31/2015 | 2 | -73 | N/A | -5 | N/A |
9/30/2015 | 1 | -66 | N/A | -1 | N/A |
6/30/2015 | 0 | -62 | N/A | 9 | N/A |
3/31/2015 | N/A | -17 | N/A | -13 | N/A |
12/31/2014 | N/A | -14 | N/A | -9 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: EDIT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: EDITDie Einnahmen des Unternehmens (37.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).
Hohe Wachstumseinnahmen: EDITDie Einnahmen des Unternehmens (37.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EDIT wird voraussichtlich in 3 Jahren unrentabel sein.